pharma · HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–POSITIVE METASTATIC BREAST CANCER · Advanced HER2-Expressing Solid Tumors. · BOLT
Bolt Biotherapeutics
Bolt Biotherapeutics patent portfolio — 7 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Redwood City, USA
- Founded
- 2015
- Employees
- 51
- Programs
- 6
- Drugs
- 4
- Patents
- 7
Bolt Biotherapeutics patents
7 pharmaceutical patents indexed for Bolt Biotherapeutics. 0 expire within 24 months.
Bolt Biotherapeutics has 7 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12325750
Anti-Dectin-2 antibodies and methods of using
granted -
US 11753474
Anti-Dectin-2 antibodies
granted -
US 11654199
Thienoazepine immunoconjugates, and uses thereof
granted -
US 11547761
Antibody adjuvant conjugates
granted -
US 11400164
Immunoconjugates targeting HER2
granted -
US 11110178
Antibody adjuvant conjugates
granted -
US 10675358
Antibody adjuvant conjugates
granted
Frequently asked questions
How many patents does Bolt Biotherapeutics have?
7 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Bolt Biotherapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.